We’re barely two months in to 2025 and Alfa Romeo have already made a statement start to the year. Only a few weeks have passed since the Italian marque unveiled their new Junior small SUV, 22,000 ...

The Alfa Romeo Tributo Italiano series is a limited edition offering of the Tonale, Stelvio, and Giulia, featuring visual and technical enhancements ...

Alfa Romeo is launching a trio of special editions, all featuring subtle touches playing up their Italian heritage.

Alfa Romeo is filling a gap left by the old MiTo and Giulietta with the Junior, which has been spied in Australia ahead of ...

Alfa Romeo has confirmed it won’t be introducing a new hatchback, with the Tonale being its sole model in the compact segment. The decision came straight from the company’s CEO, who revealed that the ...

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...

On the other hand brands like Xiaomi and Vivo kept focusing on offering better value to all price segments, which allowed them to overtake Samsung in Q4 in terms of volume share. A significant 78% ...

11:00 PM UTC · Updated ago Retail & Consumercategory Ackman's firm boosts stake in Nike, cuts Chipotle during Q4 10:56 PM UTC · Updated ago World at Workcategory Nearly 10,000 fired as Trump ...

Adjusted EPS surpassed expectations, reaching $4.18. Revenue totaled $743.5 million, just missing the estimate of $745 million. Net income dropped drastically by 24.3% year over year, reflecting ...

Among them, Romeo + Juliet star Tommy Dorfman. See the full photo shoot here, and read Dorfman’s interview below. Tommy Dorfman’s smile cuts through the gray December gloom on the day of our ...

You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy. Johnson & Johnson. "Johnson & Johnson Reports Q4 and Full-Year 2024 Results." ...

Johnson & Johnson (NYSE:JNJ) traded flat in the premarket on Wednesday after the pharma giant exceeded Street forecasts for Q4 2024, mainly due to its Innovative Medicine unit, while its MedTech ...